Search

Finite element and boundary element models of the standard wheel, damping wheels and S-type damping wheels were established and compared. The radial vibration and axial vibration of the standard wheel could be reduced to decrease the vibro-acoustic radiation. Regarding damping wheels and S-type damping wheels, the coupling between the radial vibration and axial vibrations of 1 pitch circle could be reduced to decrease the radiation noise. The vibration acceleration in the tread, rim and web plate was significantly improved after applying damping in the standard wheel. If the web plate was changed into S-type structure, the vibration acceleration of the wheel at three positions was further reduced. The radiation noise of S-type damping wheels was significantly improved. The radiation noise of the web plate was significantly greater than that of the tread, which was caused by the larger radiation area of the web plate.

Firstly, FEM (Finite Element model) of the aluminum profile is built. The structural material parameters are then given to compute the free modals. After the comparison with the experimental results, the relative error of the modal frequency can be controlled within 5 %, which meets the requirements of CAE analysis. Secondly, pulse decay method is applied to measure damping loss factor of the aluminum profile. As shown from the results, its damping loss factor is 0.15 %-0.35 % within 0 Hz-1600 Hz, which can be used as the input parameter in the subsequent computation of the transmission loss. Thirdly, FE-SEA hybrid method is used to compute the transmission loss of the aluminum profile. As known from the computational results, the transmission loss troughs of the aluminum profile are appeared at 160 Hz, 400 Hz and 800 Hz, whose change trend is basically consistent with the experimental results. Therefore, the sound insulation performance of the aluminum profile at middle and low-frequency band can be reasonably predicted by the simulation model. Finally, based on the verified model of the aluminum profile, the optimization design is conducted on its acoustic-vibro performance from the following aspects such as sound-bridge, plate thickness and structural materials. As a result, a structure with relatively optimal acoustic-vibro performance is obtained.

In the AGV system, path planning is one of the key problems. In order to improve the efficiency of the task, the paper presents a method of AGV localization and path planning aiming at the existing algorithms. The system structure of the AGV is first designed, including hardware part and software part. The AGV is then localized based on non-contact RFID in real time. The location information, speed information, communication status, video information and other information are sent to the server and monitored remotely. An improved A* algorithm is proposed to achieve real-time path planning of multi-AGV based on the traditional A* algorithm. The simulation proves that the improved A* algorithm performs more efficiently than the traditional A* algorithm, and time-consuming of the improved A* algorithm is reduced dramatically by using the proposed algorithm. Finally, the paper establishes a whole software operation platform of the AGV system, including localization, wireless control and path planning.

Hepatocellular carcinoma (HCC) is one of the most common cancers and is also a leading cause of cancer-related deaths worldwide. Until now, treatments for HCC remain limited, especially for the shortage of promising systemic therapies to replace systemic chemotherapy. Sorafenib, the first drug applied in targeted therapy for HCC, was approved and drew considerable attention. However, the efficacy and side effects of sorafenib are still unsatisfied, which make sorafenib far from ideal for treatment of HCC. Thus, developing novel therapeutics for HCC is necessary. A novel compound, ITRI-2531, is developed to improve the efficacy from sorafenib. ITRI-2531 shows cytotoxicity in HCC cell lines (Huh-7 and PLC/PRF/5) and patient-derived HCC tissue cell lines. In studies of kinase activities, ITRI-2531 suppresses the phosphorylation of MEK and ERK in PLC/PRF/5 cells and shows inhibition of multiple kinases (FLT3, FLT4, PDGFRA, PGDFRB, and VEGFR2) in KINOMEscanTM study. In in vivo studies, oral treatment of ITRI-2531 repressed subcutaneous Huh-7 and PLC/PRF/5 tumor growth in severe combined immunodeficient (SCID) mice and shows better efficacy than sorafinib. Moreover, ITRI-2531 prolongs the survival of SCID mice with orthotopic patient-derived xenograft tumor and suppresses alpha-fetoprotein in serum. On the other hand, ITRI-2531 also has good pharmacokinetic profiles. According to these results, we believe that ITRI-2531 warrants further evaluation as a new anti-HCC drug. Citation Format: Tsung-Keng Kuo, On Lee, Mai-Wei Lin, Li-Zong Lin, Chun-Min Liu, Tai-ju Hsieh, Chun-Chung Wang, Shyh-Horng Lin, Chia-Ni Chang, Hui-Chun Hsu, Nien-Tzu Chou, Chin-Pen Lai, Chih-Hung Chen, Chia-Mu Tu, Shih-Ta Chen, Yuan-Jang Tsai, Chih-Peng Liu, Jenn-Tsang Hwang, Jui-Wen Huang, Yen-Chun Chen, Chrong-Shiong Hwang, Hsiang-Wen Tseng. ITRI-2531 - A novel kinase inhibitor for treating hepatocellular carcinoma. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2015 Nov 5-9; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr B186.